CVS – Pharmacology

Among the listed drugs, Hydralazine is the one that acts as a direct arteriolar vasodilator.

✔ Hydralazine

• Directly relaxes arterial smooth muscle

• ↓ Peripheral resistance

• Used in hypertension and hypertensive emergencies

• Side effect: reflex tachycardia, lupus-like syndrome

Why the other options are incorrect

❌ Spironolactone
Aldosterone antagonist (potassium-sparing diuretic), not a vasodilator.

❌ Furosemide
Loop diuretic — increases Na⁺/water excretion, not a vasodilator.

❌ Metoprolol
β₁-blocker — reduces heart rate and cardiac output, not a vasodilator.

❌ Verapamil
Calcium channel blocker — decreases cardiac contractility and AV conduction, not used primarily as a vasodilator (DHP CCBs like nifedipine/amlodipine are vasodilators, but Verapamil is non-DHP).

Class I antiarrhythmic drugs (Class IA, IB, IC) all share one fundamental mechanism:

✔ They block fast voltage-gated Na⁺ channels in cardiac myocytes.

This action:

• Slows Phase 0 depolarization

• Decreases conduction velocity

• Helps suppress abnormal pacemaker activity

• Stabilizes the cardiac membrane

All subclasses differ in strength of Na⁺ block and effect on action potential duration, but Na⁺ channel blockade is the core mechanism.

Why the other options are incorrect

❌ Ca²⁺ channel blockade
Class IV drugs (Verapamil, Diltiazem).

❌ K⁺ channel blockade
Class III drugs (Amiodarone, Sotalol).

❌ Na⁺ channel opening
No antiarrhythmic drug works by opening sodium channels.

❌ K⁺ channel opening
Not a primary mechanism of antiarrhythmics.

Angiotensin Receptor Blockers (ARBs) block AT₁ receptors, preventing the action of angiotensin II → vasodilation, reduced aldosterone, lowered BP.

Losartan is the classic prototype ARB.

Common ARBs include:

• Losartan

• Valsartan

• Irbesartan

• Telmisartan

• Candesartan

Why the other options are incorrect

❌ Hydralazine
Direct arteriolar vasodilator.

❌ Metoprolol
Selective β₁-blocker.

❌ Labetalol (Lavetalol)
Combined α₁ + β-blocker.

❌ Prazosin
Selective α₁-blocker.

Only Losartan is an ARB.

A persistent, dry cough is the classic adverse effect of ACE inhibitors.
Captopril is an ACE inhibitor.

Why ACE inhibitors cause cough

• ACE inhibitors block degradation of bradykinin.

• ↑ Bradykinin levels lead to:

  • Persistent dry cough

  • Sometimes angioedema

This is the hallmark side effect of ACE inhibitors.

Why the other options are incorrect

❌ Nifedipine
Calcium channel blocker → causes flushing, edema, headache — not cough.

❌ Metoprolol
β₁-blocker → causes bradycardia, fatigue — not cough.

❌ Prazosin
α₁-blocker → causes orthostatic hypotension — not cough.

❌ Losartan
ARB → does NOT cause cough because it does not increase bradykinin.
(Used as an alternative when ACE inhibitors cause cough.)

Verapamil is a non-dihydropyridine calcium channel blocker. Its mechanism of action:

• Blocks L-type (slow) Ca²⁺ channels in cardiac myocytes, nodal tissue, and vascular smooth muscle.

• In cardiac tissue, this slows phase 2 of the action potential, reducing contractility (negative inotropy) and conduction through the AV node (negative dromotropy).

• In vascular smooth muscle, it causes vasodilation, lowering systemic vascular resistance.

• Clinically, verapamil is used for angina, hypertension, and certain arrhythmias (like supraventricular tachycardia).

❌ Why the other options are incorrect

Activates Na ion channels – Verapamil does not increase sodium influx; this is unrelated to its mechanism.

Reduces blood pressure – While verapamil lowers blood pressure, this is an effect, not its primary mechanism.

Blocks K ion channels – Verapamil does not block potassium channels; potassium blockers are drugs like amiodarone or sotalol.

Increases heart rate – Verapamil may decrease heart rate by slowing AV nodal conduction; it does not increase it.

Captopril is an ACE inhibitor (Angiotensin-Converting Enzyme inhibitor). Its mechanism of action:

• Blocks ACE, which normally converts angiotensin I → angiotensin II.

• By inhibiting angiotensin II formation, it reduces vasoconstriction and aldosterone-mediated sodium and water retention, leading to lower blood pressure.

• It is used in hypertension, heart failure, and post-myocardial infarction management.

❌ Why the other options are incorrect

Hydralazine

• Direct vasodilator of arterioles.

• Does not affect the renin-angiotensin system or the formation of angiotensin.

Propranolol

• Non-selective beta-blocker.

• Reduces heart rate and cardiac output, and decreases renin release indirectly, but it does not directly inhibit angiotensin formation.

Metoprolol

• Selective beta-1 blocker.

• Similar to propranolol, it reduces renin secretion indirectly, but angiotensin formation is not directly blocked.

Digitoxin

• Cardiac glycoside used for heart failure/arrhythmias.

• Works by inhibiting Na⁺/K⁺ ATPase.

• No effect on the renin-angiotensin system.

Digoxin is a cardiac glycoside that inhibits the sodium-potassium ATPase (Na⁺/K⁺ pump) on the cardiac myocyte membrane. This inhibition is the primary mechanism of action responsible for its positive inotropic effect (increased cardiac contractility).

How it works:

1. Inhibition of Na⁺/K⁺ ATPase:

   • Leads to an increase in intracellular sodium levels.

2. Reduced sodium gradient:

   • Decreases the activity of the sodium-calcium exchanger (NCX).

3. Increased intracellular calcium:

   • Calcium stays inside the cell longer, increasing calcium availability for the contractile apparatus.
   • This results in enhanced force of contraction of the cardiac sarcomere.

4. Improved cardiac output:

   • Used in the treatment of chronic heart failure (especially when associated with atrial fibrillation) by improving cardiac efficiency.

Why the Other Options Are Incorrect:

• It brings about a decrease in the intracellular sodium:

  • False — Digoxin increases intracellular sodium by inhibiting the Na⁺/K⁺ pump.

• It decreases contractility of the cardiac sarcomere:

  • False — Digoxin increases contractility (positive inotropy) by raising intracellular calcium levels.

• It belongs to drug class of aldosterone receptor antagonists:

  • False — Aldosterone receptor antagonists (like spironolactone and eplerenone) are diuretics that reduce fluid overload, not cardiac contractility.
  • Digoxin is a cardiac glycoside, not a diuretic.

• It is used in the treatment of acute heart failure:

  • False — Digoxin is not first-line for acute heart failure.
  • It is used in chronic heart failure, especially when associated with atrial fibrillation, to control heart rate and improve contractility.

Alpha and beta-adrenoreceptor blockers inhibit:

• Beta-1 receptors: Reduce heart rate, contractility, and cardiac output
• Beta-2 receptors: Cause bronchoconstriction (to a lesser extent)
• Alpha-1 receptors: Cause vasodilation → decrease peripheral resistance and lower blood pressure

Drugs with both alpha and beta-blocking effects:

1. Labetalol:

   • Alpha-1 blockade: Causes vasodilation and reduces systemic vascular resistance
   • Beta-1 blockade: Reduces heart rate and cardiac output
   • Beta-2 blockade: Can cause bronchoconstriction
   • Clinical uses:
     • Hypertensive emergencies
     • Preeclampsia
     • Chronic hypertension
   • Side effects: Orthostatic hypotension, dizziness, bronchospasm

2. Carvedilol:

   • Alpha-1 blockade: Vasodilation → decreases afterload
   • Beta-1 blockade: Reduces heart rate and myocardial oxygen demand
   • Beta-2 blockade: Minimal compared to labetalol
   • Antioxidant properties → Protects myocardium
   • Clinical uses:
     • Chronic heart failure (improves survival)
     • Hypertension
     • Post-myocardial infarction with left ventricular dysfunction
   • Side effects: Fatigue, hypotension, bradycardia

Why the other options are incorrect:

1. Metoprolol:

   • Type: Selective beta-1 blocker (“Cardioselective“)
   • No alpha-blocking action
   • Used in: Hypertension, heart failure, arrhythmias

2. Esmolol:

   • Type: Ultra-short-acting selective beta-1 blocker
   • No alpha-blocking action
   • Used in: Acute arrhythmias, intraoperative hypertension

Conclusion:
Both labetalol and carvedilol are combined alpha and beta-blockers. They are especially valuable in hypertension and heart failure due to their dual action, providing vasodilation and heart rate control.

Beta-adrenoreceptor blockers (beta-blockers) are classified into:

• Selective beta-1 blockers (“Cardioselective“)
• Non-selective beta-blockers (block both beta-1 and beta-2 receptors)
• Mixed alpha- and beta-blockers

Atenolol:

• Type: Selective beta-1 blocker
• Target: Primarily the heart (beta-1 receptors)
• Effects:
  • Reduced heart rate (negative chronotropy)
  • Decreased contractility (negative inotropy)
  • Lower cardiac output and blood pressure
• Advantages:
  • Minimal effect on beta-2 receptors (bronchi, vasculature)
  • Safer in asthma, COPD, and peripheral vascular disease compared to non-selective beta-blockers

Why the other options are incorrect:

1. Propranolol:

   • Type: Non-selective beta-blocker (blocks both beta-1 and beta-2)
   • Effects:
     • Beta-1 blockade: Decreases heart rate and blood pressure
     • Beta-2 blockade: Causes bronchoconstriction, vasoconstriction, and reduced glycogenolysis
   • Not cardioselective, contraindicated in asthma and COPD

2. Timolol:

   • Type: Non-selective beta-blocker
   • Primary use: Topical treatment for glaucoma
   • Action: Reduces aqueous humor production, lowering intraocular pressure

3. Labetalol:

   • Type: Mixed alpha- and beta-blocker
   • Effects:
     • Beta-1 blockade: Reduces heart rate and contractility
     • Beta-2 blockade: Causes bronchoconstriction
     • Alpha-1 blockade: Causes vasodilation, lowering systemic vascular resistance
   • Clinical use: Hypertensive emergencies, pheochromocytoma

4. Acebutolol:

   • Type: Selective beta-1 blocker with intrinsic sympathomimetic activity (ISA)
   • ISA: Partial agonist activity while blocking beta-1 receptors
   • Effect: Less reduction in resting heart rate and cardiac output compared to other beta-blockers
   • Not preferred in patients with ischemic heart disease due to residual sympathetic activity

Conclusion:
Atenolol is the best example of a selective beta-1 adrenoreceptor blocker, making it cardioselective. It’s often preferred in hypertension, angina, and post-myocardial infarction management because it minimizes bronchospasm risk and doesn’t significantly affect beta-2 receptors.

Ganglion blockers inhibit nicotinic receptors (Nn) at autonomic ganglia, leading to inhibition of both sympathetic and parasympathetic nervous systems.

Trimethaphan is a classic ganglion blocker used for:

• Hypertensive emergencies (though it’s rarely used now)
• Controlled hypotension during surgical procedures

Effects:

• Decreased sympathetic tone → Vasodilation → Reduced blood pressure
• Parasympathetic blockade → Tachycardia, urinary retention, dry mouth, constipation

Why it’s rarely used:
Severe side effects due to broad autonomic blockade.

Why the other options are incorrect:

1. Reserpine:

   • Mechanism: Depletes norepinephrine (NE) from sympathetic nerve endings by inhibiting vesicular monoamine transporter (VMAT).
   • Not a ganglion blocker — it works postganglionically on adrenergic neurons.
   • Side effects: Depression, sedation, nasal congestion, gastrointestinal issues.

2. Propranolol:

   • Mechanism: Non-selective beta-blocker → Blocks beta-1 and beta-2 adrenergic receptors.
   • No action on autonomic ganglia.
   • Effects: Reduces heart rate, contractility, and cardiac output.

3. Clonidine:

   • Mechanism: Alpha-2 adrenergic agonist → Centrally reduces sympathetic outflow from the brainstem.
   • Not a ganglion blocker — acts on the CNS, not peripheral autonomic ganglia.
   • Side effects: Sedation, dry mouth, rebound hypertension on abrupt withdrawal.

4. Nicotine:

   • Mechanism: Nicotinic receptor agonist (Nn) at autonomic ganglia.
   • Stimulates, rather than blocks ganglia.
   • Biphasic effect:
     • Low doses: Stimulation
     • High doses: Desensitization and blockade
   • Not used as an antihypertensive.

Conclusion:
Trimethaphan is the true ganglion blocker among these options, acting on nicotinic (Nn) receptors in autonomic ganglia, leading to potent but nonspecific autonomic inhibition. Due to its broad and severe side effects, its clinical use is extremely limited today.

ACE inhibitors (like enalapril, lisinopril, and captopril) work by blocking the conversion of angiotensin I to angiotensin II.

Let’s break down their dual action:

1. Inhibition of Angiotensin II formation:

   • Angiotensin II is a potent vasoconstrictor. By reducing its levels, ACE inhibitors lower blood pressure and reduce afterload.

2. Decreased Bradykinin Breakdown:

   • Angiotensin-converting enzyme (ACE) also breaks down bradykinin, a vasodilator.
   • By inhibiting ACE, these drugs increase bradykinin levels, leading to:
     • Vasodilation → Decreased peripheral resistance
     • Increased prostaglandins and nitric oxide (NO) → Enhanced blood flow

Key Clinical Point:
The increased bradykinin levels are responsible for the persistent dry cough seen in up to 20% of patients on ACE inhibitors.

Why the other options are incorrect:

1. Alpha-adrenoreceptor blockers (like prazosin):

   • Mechanism: Block alpha-1 adrenergic receptors → Vasodilation
   • No effect on bradykinin metabolism.

2. Ganglion blockers (like hexamethonium):

   • Mechanism: Block nicotinic receptors in autonomic ganglia → Reduced sympathetic tone
   • Not used clinically due to severe side effects.
   • No role in bradykinin metabolism.

3. Angiotensin receptor blockers (ARBs) (like losartan, valsartan):

   • Mechanism: Block angiotensin II receptors (AT1) → Vasodilation
   • Unlike ACE inhibitors, ARBs do not affect bradykinin levels.
   • Fewer side effects, including no dry cough.

4. Beta-adrenoreceptor blockers (like metoprolol, propranolol):

   • Mechanism: Block beta-adrenergic receptors → Reduced heart rate and contractility
   • No influence on bradykinin metabolism.

Conclusion:
ACE inhibitors are unique in their ability to decrease bradykinin metabolism, leading to increased bradykinin levels and additional vasodilatory effects. This mechanism explains the efficacy of ACE inhibitors in hypertension management and their characteristic side effects like dry cough and angioedema.

Atenolol is a cardioselective beta-1 adrenergic antagonist (beta-blocker). It primarily blocks beta-1 receptors located in the heart, leading to:

• Reduced heart rate (negative chronotropy)
• Decreased force of contraction (negative inotropy)
• Lower blood pressure by reducing cardiac output
• Decreased oxygen demand, which helps in angina management

Uses:

• Hypertension
• Angina pectoris
• Post-myocardial infarction care
• Arrhythmias

Why “cardioselective” matters:
Since beta-2 receptors are found in bronchial smooth muscle, non-selective beta-blockers can cause bronchoconstriction. Cardioselective beta-1 blockers like atenolol are safer in patients with asthma or COPD because they avoid blocking beta-2 receptors in the lungs.

Why the Other Options Are Incorrect:

• Propranolol:

  • Non-selective beta-blocker → Blocks both beta-1 and beta-2 receptors.
  • Can cause bronchoconstriction, so not ideal for asthma/COPD patients.

• Pindolol:

  • Non-selective beta-blocker with intrinsic sympathomimetic activity (ISA).
  • Partially stimulates beta receptors while blocking them, leading to lesser bradycardia but reduced effectiveness in heart rate control.

• Nadolol:

  • Non-selective beta-blocker with a long half-life.
  • Also affects beta-2 receptors, which can lead to bronchospasm.

• None of these:

  • Incorrect because atenolol is a well-established cardioselective beta-1 blocker.

Sodium nitroprusside is the drug of choice in hypertensive emergencies because:

• Mechanism of action: It’s a direct-acting vasodilator that releases nitric oxide (NO), leading to smooth muscle relaxation in blood vessels.
• Effect: Causes rapid reduction in blood pressure by dilating both arteries and veins, leading to decreased afterload and preload.
• Onset: Immediate, within seconds of IV administration.
• Duration: Short-acting, allowing precise titration of blood pressure.
• Indications: Used in hypertensive crises, aortic dissection, and acute heart failure when rapid BP control is crucial.

Why the Other Options Are Incorrect:

• Captopril:

  • An ACE inhibitor used for long-term management of hypertension, not emergencies.
  • Slower onset of action compared to sodium nitroprusside.

• Propranolol:

  • A non-selective beta-blocker, used for chronic hypertension, angina, and arrhythmias.
  • Not fast-acting enough for hypertensive emergencies.

• Atropine:

  • An anticholinergic drug that increases heart rate by inhibiting the parasympathetic nervous system.
  • Used in bradycardia, not for hypertension.

• None of these:

  • Incorrect because sodium nitroprusside is clearly the most commonly used drug in hypertensive emergencies.

Why Quinidine is Correct (Class IA Antiarrhythmic)

Class IA antiarrhythmic drugs block Na⁺ channels (moderate block) and also prolong action potential duration by blocking K⁺ channels.
Quinidine is the classic Class IA drug along with Procainamide and Disopyramide.

Why the Other Options Are Incorrect

❌ Bretylium

• This is a Class III antiarrhythmic (K⁺ channel blocker).

• Used mainly for refractory ventricular arrhythmias.

❌ Phenytoin

• This is a Class IB antiarrhythmic (weak Na⁺ channel blocker).

• Used for digitalis-induced arrhythmias.

❌ Verapamil

• This is a Class IV drug (Ca²⁺ channel blocker).

• Acts mainly on the AV node.

❌ Amiloride

• Not an antiarrhythmic.

• It is a potassium-sparing diuretic (ENaC blocker).

Mechanism of Action of Propranolol in Angina:

Propranolol is a non-selective beta-blocker, meaning it blocks both beta-1 and beta-2 adrenergic receptors. Its primary mechanism of action in treating angina involves:

1. Reduction of Heart Rate (Negative Chronotropy):
   • By blocking beta-1 receptors in the heart, propranolol inhibits the effects of adrenaline (epinephrine) and noradrenaline (norepinephrine), which normally increase heart rate. This slows down the heart rate, reducing the workload on the heart.
2. Reduction of Myocardial Contractility (Negative Inotropy):
   • Propranolol also decreases the force of myocardial contraction by blocking beta-1 receptors. This further reduces the heart’s oxygen demand.
3. Decreased Myocardial Oxygen Demand:
   • Angina occurs when there is an imbalance between myocardial oxygen supply and demand. By reducing heart rate and contractility, propranolol lowers the heart’s oxygen requirements, preventing or alleviating angina symptoms.

Why the Other Options Are Incorrect:

1. Increase of heart rate and myocardial contractility to compensate myocardial oxygen demand:
   • This is incorrect because increasing heart rate and contractility would raise myocardial oxygen demand, worsening angina. Beta-blockers like propranolol do the opposite.
2. Vasodilation to counter coronary vasospasms:
   • While vasodilation can help in certain types of angina (e.g., variant or Prinzmetal angina caused by coronary vasospasms), propranolol is not primarily a vasodilator. Calcium channel blockers (e.g., nifedipine) are more effective for this purpose.
3. None of these:
   • This is incorrect because propranolol does have a well-defined mechanism of action in angina, as described above.
4. Increased sympathetic stimulation of heart for the survival of patient:
   • This is incorrect because propranolol blocks sympathetic stimulation of the heart, which is how it reduces heart rate and contractility to alleviate angina.

Why Does Histamine Cause a Rapid Drop in Blood Pressure?

Histamine is a potent vasodilator that leads to a sudden drop in blood pressure by causing:

1. Vasodilation of Arterioles

   • Histamine binds to H1 receptors on vascular smooth muscle, causing relaxation and dilation of blood vessels.
   • This leads to a significant drop in systemic vascular resistance (SVR), reducing blood pressure.

2. Increased Capillary Permeability

   • Histamine also increases capillary permeability, leading to fluid leakage from blood vessels into tissues.
   • This results in a decrease in effective circulating blood volume, further lowering blood pressure.

3. Role in Anaphylactic Shock

   • In severe allergic reactions (anaphylaxis), massive histamine release from mast cells and basophils causes sudden hypotension, requiring emergency treatment with epinephrine.

Breakdown of Incorrect Options:

1. Angiotensin II → Incorrect

   • Angiotensin II is a potent vasoconstrictor that raises blood pressure, not lowers it.
   • It increases systemic vascular resistance (SVR) and promotes aldosterone secretion, leading to sodium and water retention, which raises blood pressure.

2. Thromboxane A2 → Incorrect

   • Thromboxane A2 (TXA2) is a vasoconstrictor and platelet aggregator.
   • It plays a role in clot formation and increasing blood pressure, not lowering it.

3. Norepinephrine → Incorrect

   • Norepinephrine (NE) is a strong vasoconstrictor that increases blood pressure by stimulating alpha-1 receptors on blood vessels.
   • It is used to treat hypotension, not cause it.

4. Nicotine → Incorrect

   • Nicotine stimulates the sympathetic nervous system (SNS), causing vasoconstriction and increased blood pressure.
   • Chronic nicotine use leads to hypertension, not hypotension.

Understanding the Effects of Atropine on Heart Rate

Atropine is a muscarinic antagonist that blocks the parasympathetic (vagal) influence on the heart, specifically at the SA node. This results in an increased heart rate, which is called a positive chronotropic effect.

Key Definitions:

• Chronotropic effects → Affect heart rate

  • Positive chronotropic effect → Increases heart rate (e.g., atropine, epinephrine).
  • Negative chronotropic effect → Decreases heart rate (e.g., beta-blockers, acetylcholine).

• Inotropic effects → Affect contractility (force of contraction)

  • Positive inotropic effect → Increases contractility (e.g., digoxin, epinephrine).
  • Negative inotropic effect → Decreases contractility (e.g., beta-blockers, calcium channel blockers).

• Dromotropic effects → Affect conduction speed through the AV node

  • Positive dromotropic effect → Increases AV node conduction (e.g., epinephrine).
  • Negative dromotropic effect → Decreases AV node conduction (e.g., verapamil).

Breakdown of Incorrect Options:

1. Positive inotropic effect → Incorrect

   • Inotropic effects relate to contractility, not heart rate.
   • Atropine does not increase contractile force; it only raises heart rate by inhibiting parasympathetic activity.

2. Negative chronotropic effect → Incorrect

   • A negative chronotropic effect means decreasing heart rate, which is the opposite of atropine’s action.
   • Drugs like beta-blockers and acetylcholine cause negative chronotropic effects.

3. Negative inotropic effect → Incorrect

   • Atropine does not weaken heart contraction; it only affects heart rate.
   • Negative inotropes include beta-blockers and calcium channel blockers.

4. Negative dromotropic effect → Incorrect

   • A negative dromotropic effect slows AV node conduction, often seen with verapamil or beta-blockers.
   • Atropine does not slow conduction but instead increases heart rate via SA node stimulation.

Beta-1 adrenergic receptors are the primary receptors on the heart that mediate the effects of the sympathetic nervous system. When activated by norepinephrine (released from sympathetic nerve endings) or epinephrine (released from the adrenal medulla), beta-1 receptors increase:

• Heart rate (positive chronotropy)
• Force of contraction (positive inotropy)
• Conduction velocity (positive dromotropy)

These effects enhance cardiac output, which is essential during the “fight or flight” response.

Why the Other Options Are Incorrect:

1. Gamma receptors
   There are no “gamma receptors” in the context of the sympathetic nervous system or cardiac physiology. This is not a valid receptor type.
2. Beta-2 adrenergic receptors
   Beta-2 adrenergic receptors are primarily found in smooth muscle of the airways, blood vessels, and other tissues. They mediate relaxation of smooth muscle (e.g., bronchodilation and vasodilation) but are not involved in the sympathetic effects on the heart.
3. Alpha receptors
   Alpha receptors (alpha-1 and alpha-2) are involved in vasoconstriction and other sympathetic responses but do not play a significant role in mediating the sympathetic effects on the heart. Alpha-1 receptors are found in vascular smooth muscle, while alpha-2 receptors are primarily presynaptic and regulate neurotransmitter release.
4. Cholinergic receptors
   Cholinergic receptors (e.g., muscarinic M2 receptors) mediate the effects of the parasympathetic nervous system on the heart. Activation of these receptors decreases heart rate and contractility, which is the opposite of the sympathetic effect.

Captopril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the formation of angiotensin II by inhibiting the ACE enzyme.

Mechanism of Action:

• Angiotensin II is a potent vasoconstrictor that increases blood pressure and stimulates aldosterone secretion, leading to sodium and water retention.
• By inhibiting ACE, captopril reduces angiotensin II levels, resulting in:
  • Vasodilation (lowering blood pressure).
  • Reduced sodium and water retention (decreasing blood volume).
  • Decreased cardiac workload (beneficial in heart failure).

Uses:

• Hypertension
• Heart failure
• Diabetic nephropathy
• Post-myocardial infarction protection

Why the Other Options Are Incorrect?

• Propranolol (Beta-blocker):

  • Blocks β1 and β2 receptors, reducing heart rate and cardiac output, but does not inhibit angiotensin formation.
  • It reduces renin secretion, but indirectly.

• Digitoxin (Cardiac glycoside):

  • Inhibits Na⁺/K⁺-ATPase, increasing cardiac contractility in heart failure.
  • No direct effect on angiotensin formation.

• Hydralazine (Vasodilator):

  • Directly relaxes arterial smooth muscle, reducing blood pressure.
  • Does not affect the renin-angiotensin system.

• Metoprolol (Beta-1 selective blocker):

  • Reduces sympathetic stimulation of the heart, decreasing heart rate and contractility.
  • It reduces renin release from the kidneys, but does not inhibit angiotensin formation directly.

A prodrug is a medication that is inactive in its administered form and requires metabolic conversion in the body to become active.

Among the given options, Lovastatin is the only prodrug.

• Lovastatin is an inactive lactone that is hydrolyzed in the liver to produce its active form, β-hydroxy acid, which inhibits HMG-CoA reductase.
• It is used to lower cholesterol levels by reducing hepatic cholesterol synthesis.

Why the Other Options Are Incorrect

• Atorvastatin, Fluvastatin, and Rosuvastatin

  • These are already in active form when administered.
  • They directly inhibit HMG-CoA reductase, the key enzyme in cholesterol biosynthesis.

• None of these:

  • Incorrect, because Lovastatin is a prodrug.

Angiotensin-converting enzyme (ACE) inhibitors (e.g., enalapril, lisinopril, captopril) are widely used for hypertension and heart failure. They work by inhibiting ACE, which converts angiotensin I to angiotensin II, a potent vasoconstrictor.

How ACE Inhibitors Cause Dry Cough:

1. ACE normally degrades bradykinin, a peptide that causes vasodilation and increased vascular permeability.
2. When ACE is inhibited, bradykinin levels rise.
3. Increased bradykinin leads to irritation of sensory nerves in the lungs, triggering a persistent dry cough.
4. This cough is non-productive, nagging, and can be bothersome enough to require stopping the medication.

❌Why the Other Options Are Incorrect:

1. Fever 

   • Fever is not a common side effect of ACE inhibitors.
   • However, angioedema, another bradykinin-related effect, can cause swelling of the face, lips, and airways, but it does not typically cause fever.

2. Skin rash and bronchodilation 

   • Skin rash can occur with ACE inhibitors, but bronchodilation is not an expected effect.
   • In fact, increased bradykinin can cause bronchoconstriction, not bronchodilation.

3. Excessive sputum production 

   • ACE inhibitor-induced cough is dry, meaning there is no excess sputum production.
   • Increased mucus production is more typical of respiratory infections or conditions like COPD and asthma.

4. Bronchoconstriction

   • While bradykinin can contribute to mild airway irritation, significant bronchoconstriction is not a primary adverse effect of ACE inhibitors.
   • Patients with asthma may experience worsening symptoms, but bronchoconstriction is not the main reason for ACE inhibitor discontinuation—dry cough and angioedema are.

Nitrates, such as nitroglycerin, are potent vasodilators primarily used in the treatment of angina pectoris. Their primary mechanism of action involves releasing nitric oxide (NO), which stimulates guanylate cyclase to increase cGMP levels, leading to smooth muscle relaxation.

How Nitrates Decrease Venous Return:

• Primary Effect: Venodilation (dilation of veins) → This leads to increased venous pooling of blood.
• Reduced Preload: Since less blood returns to the heart, preload (end-diastolic volume) decreases.
• Lower Myocardial Oxygen Demand: Less ventricular stretching reduces oxygen demand, making nitrates beneficial for angina relief.

Thus, nitrates primarily decrease venous return, reducing cardiac workload and oxygen consumption.

Why the Other Options Are Incorrect:

1. “Nitroglycerine is placed under the tongue because if swallowed it would be destroyed by gastric juice” (Incorrect)

   • The main reason nitroglycerin is given sublingually is to bypass first-pass metabolism in the liver, not because of destruction by gastric juice.
   • If swallowed, nitroglycerin is rapidly metabolized by the liver (hepatic metabolism), making it ineffective.

2. “They are more effective as prophylactic measures taken daily than to relieve an anginal attack” (Incorrect)

   • Nitrates are more effective for acute anginal relief rather than long-term prevention.
   • Beta-blockers and calcium channel blockers are preferred for chronic prophylaxis of angina.
   • Tolerance develops quickly with long-term nitrate use, reducing effectiveness.

3. “They are selective coronary dilators” (Incorrect)

   • Nitrates cause both systemic and coronary vasodilation.
   • However, they primarily act on veins, and their coronary effects are not selective.
   • Additionally, coronary dilation does not significantly improve blood flow in ischemic areas due to the coronary steal phenomenon.

4. “They constrict meningeal blood vessels causing headache” (Incorrect)

   • Nitrates dilate meningeal blood vessels, not constrict them.
   • This dilation leads to headaches, a common side effect.

Antiarrhythmic drugs are classified using the Vaughan-Williams classification, where Class 1 drugs are sodium channel blockers (Na+ channel blockers) that act on cardiac action potentials.

Class 1 is further divided into:

• Class 1A: Moderate Na+ channel blockade (e.g., Quinidine, Procainamide)
• Class 1B: Weak Na+ channel blockade (e.g., Lidocaine, Mexiletine, Tocainide, Phenytoin)
• Class 1C: Strong Na+ channel blockade (e.g., Flecainide, Propafenone)

Why Flecainide is Class 1C:

• It strongly inhibits fast Na+ channels → Slows Phase 0 depolarization in cardiac action potential.
• Minimal effect on action potential duration (unlike Class 1A or 1B).
• Used for supraventricular and ventricular arrhythmias, especially atrial fibrillation and refractory ventricular tachycardia.
• Proarrhythmic effects → Can worsen arrhythmias, especially in structural heart disease.

Thus, Flecainide is a Class 1C antiarrhythmic because it strongly blocks Na+ channels and slows conduction without significantly affecting repolarization.

Why the Other Options Are Incorrect:

1. Lidocaine (Incorrect)

   • Class 1B antiarrhythmic.
   • Weak Na+ channel blockade, primarily acts on ischemic or depolarized Purkinje and ventricular tissue.
   • Used for ventricular arrhythmias, especially post-myocardial infarction (MI).

2. Tocainide (Incorrect)

   • Class 1B antiarrhythmic.
   • Similar to Lidocaine, but orally active.
   • Used for ventricular arrhythmias.

3. Phenytoin (Incorrect)

   • Class 1B antiarrhythmic.
   • Primarily used as an anticonvulsant but can also treat certain ventricular arrhythmias (especially digitalis-induced arrhythmias).

4. Mexiletine (Incorrect)

   • Class 1B antiarrhythmic.
   • Oral version of Lidocaine, used for chronic ventricular arrhythmias.

Milrinone is a phosphodiesterase-3 (PDE-3) inhibitor that is primarily used in the short-term management of acute heart failure and cardiogenic shock. It is classified as an ionotropic and vasodilatory agent (inodilator), meaning it increases myocardial contractility and causes vasodilation.

How Milrinone Works:

1. Inhibition of Phosphodiesterase-3 (PDE-3):

   • PDE-3 is an enzyme that breaks down cyclic AMP (cAMP) in cardiac and vascular smooth muscle cells.
   • Milrinone inhibits PDE-3, leading to an increase in cAMP levels.

2. Effects on the Heart:

   • Increased cAMP enhances calcium availability inside cardiac muscle cells, leading to stronger myocardial contractions (positive inotropic effect).
   • Improves cardiac output without significantly increasing myocardial oxygen demand.

3. Effects on Blood Vessels:

   • Increased cAMP causes vasodilation, reducing afterload and improving perfusion.

Thus, Milrinone is preferred because it directly stimulates myocardial contractility by increasing intracellular cAMP levels in cardiac muscle cells.

Why the Other Options Are Incorrect:

1. It gives long-term inotropic support in the case of heart failure (Incorrect)

   • Milrinone is not used for long-term therapy due to its risk of arrhythmias and increased mortality in chronic heart failure patients.
   • It is primarily used short-term in acute heart failure or cardiogenic shock.

2. It prevents thrombocytopenia (Incorrect)

   • Milrinone does not prevent thrombocytopenia.
   • In fact, it has been associated with a risk of thrombocytopenia in some patients.

3. It has a long life (Incorrect)

   • Milrinone has a short half-life (2-4 hours) and requires continuous IV infusion in critical care settings.
   • It is not preferred for its duration of action.

4. It selectively inhibits cAMP and phosphodiesterase type IV enzymes (Incorrect)

   • Milrinone inhibits PDE-3, not PDE-4.
   • PDE-4 inhibitors (e.g., roflumilast) are used for inflammatory conditions like COPD and not for cardiac support.

Why Statins are Correct:

Statins are a class of drugs that reduce LDL cholesterol by inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver. By blocking this enzyme, statins decrease intracellular cholesterol levels, leading to an upregulation of LDL receptors on hepatocytes. This increases the clearance of LDL cholesterol from the bloodstream, resulting in lower LDL levels. Statins are first-line therapy for hyperlipidemia and are widely used to reduce the risk of cardiovascular disease.

Why the Other Options Are Incorrect:

Calcium channel blockers

• Calcium channel blockers (e.g., amlodipine, diltiazem) are used to treat hypertension and angina by relaxing blood vessels and reducing heart rate. They do not affect cholesterol levels.

Beta blockers

• Beta blockers (e.g., metoprolol, atenolol) are used to treat hypertension, heart failure, and arrhythmias by blocking the effects of adrenaline on the heart. They do not lower LDL cholesterol.

Diuretics

• Diuretics (e.g., furosemide, hydrochlorothiazide) are used to treat hypertension and edema by increasing urine production and reducing blood volume. They do not have a significant effect on LDL cholesterol.

ACE inhibitors

• ACE inhibitors (e.g., lisinopril, enalapril) are used to treat hypertension and heart failure by blocking the production of angiotensin II, a potent vasoconstrictor. They do not lower LDL cholesterol.

Why Diltiazem is Correct:

Diltiazem is a calcium channel blocker (CCB) that specifically inhibits L-type calcium channels. These channels are found in cardiac and smooth muscle cells and play a key role in regulating calcium influx, which is necessary for muscle contraction. By blocking these channels, diltiazem reduces calcium entry into cells, leading to vasodilation (relaxation of blood vessels) and decreased heart rate and contractility. This makes diltiazem useful for treating conditions like hypertension, angina, and arrhythmias.

Why the Other Options Are Incorrect:

 Esmolol

• Esmolol is a beta-1 selective adrenergic receptor antagonist (beta-blocker). It works by blocking the effects of adrenaline on the heart, reducing heart rate and contractility, but it does not affect L-type calcium channels.

 Metoprolol

• Metoprolol is also a beta-1 selective adrenergic receptor antagonist (beta-blocker). Like esmolol, it reduces heart rate and contractility by blocking beta-1 receptors, not calcium channels.

 Amiodarone

• Amiodarone is a class III antiarrhythmic drug that primarily blocks potassium channels, prolonging the action potential duration and refractory period. It also has some beta-blocking and calcium channel-blocking effects, but these are not its primary mechanism of action.

 Furosemide

• Furosemide is a loop diuretic that inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, leading to increased urine production. It has no effect on L-type calcium channels

Explanation:

Why Aspirin is Correct:

Aspirin is the first-line antiplatelet medication for the treatment of acute myocardial infarction (AMI). It works by irreversibly inhibiting cyclooxygenase-1 (COX-1), which prevents the formation of thromboxane A2, a potent promoter of platelet aggregation. Administering aspirin as soon as possible during an AMI reduces the risk of further clot formation and improves outcomes. The typical dose is 162–325 mg chewed (to ensure rapid absorption) at the time of diagnosis.

Why the Other Options Are Incorrect:

 Clopidogrel

• Clopidogrel is an antiplatelet medication that inhibits the P2Y12 receptor on platelets. While it is often used in combination with aspirin for AMI (dual antiplatelet therapy), it is not the first-line single agent for initial treatment.

 Heparin

• Heparin is an anticoagulant, not an antiplatelet agent. It is used in AMI to prevent further clot formation but does not directly affect platelet aggregation. It is often used alongside aspirin and other antiplatelet therapies.

 Warfarin

• Warfarin is an oral anticoagulant that inhibits vitamin K-dependent clotting factors. It is not used in the acute treatment of AMI and does not have antiplatelet effects.

 Enoxaparin

• Enoxaparin is a low-molecular-weight heparin (LMWH) and acts as an anticoagulant. Like heparin, it is used to prevent clot extension but is not an antiplatelet medication.

Why Throbbing Headache is Correct:

Nitroglycerin is a vasodilator commonly used to treat angina and heart failure. One of its most common side effects is a throbbing headache, which occurs due to the dilation of blood vessels in the brain. This vasodilation increases blood flow to the cranial arteries, leading to the characteristic headache. While this side effect can be uncomfortable, it is generally not dangerous and often diminishes with continued use as the body adapts.

Why the Other Options Are Incorrect:

Seizures

• Seizures are not a typical side effect of nitroglycerin. Nitroglycerin primarily affects the cardiovascular system and does not have significant effects on the central nervous system that would lead to seizures.

Anemia

• Anemia is not associated with nitroglycerin use. Nitroglycerin does not affect red blood cell production or cause blood loss, which are the primary mechanisms of anemia.

Edema

• Edema (swelling) is not a direct side effect of nitroglycerin. However, nitroglycerin can cause reflex tachycardia or hypotension, which might indirectly contribute to fluid retention in some cases. This is not a primary or common side effect.

Constipation

• Constipation is not a side effect of nitroglycerin. Nitroglycerin primarily affects smooth muscle in blood vessels, not the gastrointestinal tract.

A loading dose is a large initial dose of a drug given to quickly achieve the desired plasma concentration, especially in emergencies where waiting for steady state would take too long.

This allows rapid therapeutic effect, which matches the scenario described.

Why the other options are incorrect

❌ Lethal dose

• The amount that causes death—not therapeutic.

❌ Maintenance dose

• Smaller, repeated doses used to maintain drug levels after the loading dose.

❌ Pediatric dose

• Dose adjusted for children; not relevant here.

❌ Toxic dose

• Dose that causes harmful effects; not intended in treatment.